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Background: Recurrence patterns in patients who have undergone curative gastrectomy for advanced gastric
carcinoma can be classified as peritoneal, hematogenous, or lymphatic. The aim of this study was to clarify
differences in risk factors between these different types of recurrence pattern.
Methods: Postoperative courses, including sites of recurrence and periods between surgery and recurrence, of
patients who had undergone curative gastrectomy for advanced gastric carcinoma (more than pT2 invasion) were
surveyed in detail. Clinicopathological factors were examined as potential independent risk factors for each
recurrence pattern, based on recurrence-free survival, using multivariate analysis.
Results: Multivariate analysis identified depth of tumor invasion (pT4 vs. pT2/3; hazard ratio (HR), 7.05; P < 0.001),
number of lymph node metastases (pN2/3 vs. pN0/1; HR, 4.02; P = 0.001), and histological differentiation (G3/4 vs.
G1/2; HR, 2.22; P = 0.041) as independent risk factors for peritoneal metastasis. The number of lymph node
metastases (HR, 26.21; P < 0.001) and venous vessel invasion (HR, 5.09; P = 0.001) were identified as independent
risk factors for hematogenous metastasis. The number of lymph node metastases (HR, 6.00; P = 0.007) and depth of
tumor invasion (HR, 4.70; P = 0.023) were identified as independent risk factors for lymphatic metastasis.
Conclusions: This study clarified differences in risk factors between various patterns of recurrence. Careful
examination of risk factors could help prevent oversight of recurrences and improve detection of recurrences
during follow-up. The number of lymph node metastases represents an independent risk factor for all three
patterns of recurrence; thus, patients with multiple lymph node metastases warrant particular attention.
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Even after performing curative surgical resection, death
from recurrence is frequent among patients with ad-
vanced gastric carcinoma. However, early detection of
recurrence sites is sometimes difficult. One reason for
this is that recurrence can show various patterns. Recur-
rence patterns in patients who have undergone curative
surgical resection for advanced gastric carcinoma can be
classified as peritoneal, hematogenous, or lymphatic* Correspondence: y.nakanishi@mac.com
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reproduction in any medium, provided the ormetastases. Clarification of the differences in risk factors
between these patterns of recurrence may be helpful in
postoperative follow-up to ensure that recurrences are
not missed and to allow additional therapy, including
chemo- or radiotherapy, to be initiated early in the re-
currence phase.
The aim of this study, therefore, was to clarify differ-
ences in risk factors between these three recurrence pat-
terns among patients who had undergone curative
resection for advanced gastric carcinoma.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patients
Patients with synchronous primary neoplasms of other
organs or who had undergone neoadjuvant chemother-
apy were excluded from the study. A total of 132 pa-
tients (87 men, 45 women) who had undergone surgical
curative resection and had been pathologically diagnosed
with advanced gastric carcinoma (defined as carcinoma
extending more deeply than the muscularis propria) be-
tween April 1999 and December 2011 at the National
Hospital Organization at Hakodate Hospital, Hakodate,
Japan, were registered in the study. All these patients
showed negative results on intra-operative peritoneal cy-
tology. The median age at the time of surgery was 69
years (range, 30 to 92 years). Surgical procedures for
these patients involved total gastrectomy for 53 patients,
distal gastrectomy for 70, proximal gastrectomy for 6,
and pancreaticoduodenectomy for 3. The extent of
lymph node dissection was D2 level in 71 patients and
below D2 in 61, according to the 2010 Japanese gastric
cancer treatment guidelines [1]. Adjuvant treatment
after surgical resection was administered at the discre-
tion of the individual surgeon. A total of 61 patients
(including 3 of 19 patients in stage 1, 15 of 51 in stage 2,
and 43 of 61 in stage 3 according to the TNM Classifica-
tion of Malignant Tumors [2]) received oral administra-
tion of S-1 or UFT for approximately 1 year, or until
side effects became too strong to tolerate.
Postoperative follow-up
Most patients received regular follow-up sessions every
3 months. At each visit, a clinical examination, hemato-
logical analysis (including tumor marker assays for
carcinoembryonic antigen and carbohydrate antigen
19-9), and chest and abdominal radiography were
performed. Digestive endoscopy was performed annu-
ally. Follow-up ended in March 2012. The median
survival period for all patients was 32 months (range, 1
to 157 months).
Computed tomography of the abdomen was per-
formed every 6 months or on suspicion of clinical recur-
rence, including when an increase in tumor markers
above pathological levels was seen. Bone scintigraphy
was used for suspected bone metastasis. If an intestinal
obstruction was not improved by long tube insertion,
the patient was examined for peritoneal dissemination
and underwent surgery if necessary.
Clinicopathological factors
This study examined eight clinicopathological factors as
candidate risk factors for recurrence after curative resec-
tion of advanced gastric carcinoma: extent of the
primary tumor (pT2/3 vs. pT4); number of metastatic
lymph nodes (pN0/1 vs. pN2/3); histopathologicalgrading (G1/2, including papillary carcinoma, vs. G3/4,
including signet ring cell carcinoma, mucinous adeno-
carcinoma, in accordance with the TNM Classification
of Malignant Tumors [2]); venous invasion; lymphatic
vessel invasion; sex; age (<70 years vs. ≥70 years); and
extent of systematic lymphadenectomy (D2 or less than
D2, according to Japanese gastric cancer treatment
guidelines 2010 [1]). In this study, performance of adju-
vant chemotherapy was not examined as a candidate risk
factor of recurrence, because this factor correlated with
other factors (pT4 and pN2/3).Prognostic factors for overall survival
Risk factors for overall survival were examined using
univariate and multivariate analysis to compare them for
each pattern of recurrence.Examinations of risk factors according to patterns of
recurrence
The type of recurrence was classified on the basis of im-
aging studies or intra-operative and biopsy findings in
patients who underwent re-operation. The incidence of
recurrence depends on the time from surgical resection.
We therefore examined for risk factors associated with
the time of recurrence-free survival (RFS):
1. RFS was defined as the interval between completion
of surgery and recurrence.
2. For patients with two or three recurrence patterns
detected asynchronously, RFS for all recurrence
patterns was defined as the interval between surgery
and the first recurrence pattern.
3. Patients with two or three recurrence patterns
detected simultaneously were classified as showing
all the recurrence patterns detected.
4. In an examination for one pattern of recurrence,
data from patients with only the other recurrence
patterns were censored as of the date of occurrence
of the other recurrence patterns.
5. Data for patients who did not experience recurrence
were censored as of the date of the final observation.
6. Data for patients who died without recurrence were
censored as of the date of death.Statistical analysis
Survival curves were constructed using the Kaplan-
Meier method and differences in overall survival and
RFS on univariate analysis were evaluated using the log-
rank test. The Cox proportional hazards model was used
to perform multivariate analysis. All tests were two-
sided; values of P < 0.05 were considered statistically
significant.
Figure 1 Overall survival curves of patient with recurrence in
three recurrence patterns.
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Recurrence patterns
Among the 132 patients who underwent curative resec-
tion for advanced gastric carcinoma, 66 were alive with-
out recurrence and 6 were alive with recurrence ofTable 1 Univariate and multivariate analyses of overall surviv












G1 or G2 58 70.7
G3 or G4 74 41.2
Depth of tumor invasion
pT2 or pT3 64 77.2
pT4 68 35.6
Number of lymph node metastases
pN0 or pN1 74 72.8






Positive 48 39.4gastric carcinoma, as of March 2012, while 21 patients
had died of other diseases without evident recurrence of
gastric carcinoma and 39 had died of recurrent gastric
carcinoma.
Of the 45 patterns of recurrence, peritoneal-only,
hematogenous-only, lymphatic-only, all three patterns
combined, hematogenous with lymphatic, peritoneal
with hematogenous, and peritoneal with lymphatic pat-
terns were seen in 21, 8, 2, 4, 5, 2, and 3 patients,
respectively. Overall survival curves after surgical resec-
tion with the three recurrence patterns are shown in
Figure 1. The median overall survival period for periton-
eal, hematogenous, and lymphatic metastasis patterns
was 22.6 months (range, 7 to 115 months), 32.5 months
(8 to 72 months), and 40.5 months (8 to 72 months),
respectively. No statistical difference was seen between
the three recurrence patterns (P = 0.939).
Prognostic factors in overall survival
The impacts of clinicopathological variables on overall
survival in all 132 patients are shown in Table 1. Histo-
logical differentiation, depth of tumor invasion, numberal
at 5 Univariate P Multivariate P relative






2.15 (1.23 to 3.85)
<0.001 0.040
1
1.85 (1.03 to 3.47)
<0.001 <0.001
1
2.71 (1.53 to 4.98)
0.016
0.026
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and venous vessel invasion were identified as prognostic
factors for overall survival on univariate analysis
(P = 0.020, P < 0.001, P < 0.001, P = 0.016, and P =
0.026, respectively). On multivariate analysis, histological
differentiation, depth of primary tumor invasion, and
number of lymph node metastases were identified as
independent factors affecting overall survival (P = 0.006,
P = 0.040, and P < 0.001, respectively).
Risk factors for recurrence patterns
Peritoneal metastasis
The median RFS for the 30 patients with peritoneal me-
tastasis was 14.5 months (range, 3.4 to 64.2 months).
The impacts of clinicopathological variables on the RFS
of peritoneal recurrence are shown in Table 2. On uni-
variate analysis, histological differentiation, depth of
tumor invasion, and number of lymph node metastases
were identified as risk factors for peritoneal metastasis
(P = 0.022, P < 0.001, and P < 0.001, respectively). On
multivariate analysis, histological differentiation, depth
of tumor invasion, and number of lymph node metas-Table 2 Univariate and multivariate analyses of recurrence-fr
Variables n Cumulative rec











G1 or G2 58 20.4
G3 or G4 74 42.3
Depth of tumor invasion
pT2 or pT3 64 8.0
pT4 68 53.6
Number of lymph node metastases
pN0 or pN1 74 13.2






Positive 48 34.6tases represented independent risk factors associated
with peritoneal metastasis (P = 0.041, P < 0.001, and
P = 0.001, respectively).
Hematogenous metastasis
Recurrence sites in the 19 patients with hematogenous
recurrence were the liver in ten patients (52.6%), bone in
four (21.1%), pleura in three (15.8%), lungs in three
(15.8%), brain in two (10.5%), and intramural residual
stomach, non-resected stump or site of anastomosis, in
two (10.5%). Some patients had recurrence in more than
one site.
The median RFS of the 19 patients with peritoneal
metastasis was 14.2 months (range, 2.1 to 59.8 months).
The impacts of clinicopathological variables on RFS for
hematogenous metastasis are shown in Table 3. On uni-
variate analysis, depth of tumor invasion, number of
lymph node metastases, lymphatic vessel invasion, and
venous invasion were identified as risk factors for
hematogenous metastasis (P = 0.009, P < 0.001,
P = 0.004, and P < 0.001, respectively). On multivariate
analysis, the number of lymph node metastases andee survival for peritoneal metastasis
urrence
rs (%)







2.22 (1.03 to 5.17)
<0.001 <0.001
1
7.05 (2.42 to 30.05)
<0.001 0.001
1
4.02 (1.03 to 5.17)
0.120
0.441
Table 3 Univariate and multivariate analyses of recurrence-free survival for hematogenous metastasis
Variables n Cumulative recurrence
rate at 5-year (%)












G1 or G2 72 14.5
G3 or G4 59 31.2
Depth of tumor invasion 0.009 0.708
pT2 or pT3 64 13.0 1
pT4 68 33.1 1.23 (0.43 to 4.08)
Number of lymph node metastases <0.001 <0.001
pN0 or pN1 74 2.0 1
pN2 or pN3 58 47.7 26.21 (3.66 to 581.73)
Lymphatic invasion 0.004 0.982
Negative 45 3.3 1
Positive 87 32.5 1.03 (0.14 to 22.26)
Venous invasion <0.001 0.001
Negative 84 12.9 1
Positive 48 49.3 5.09 (1.89 to 14.87)
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factors for hematogenous metastasis (P < 0.001 and
P = 0.001, respectively).
Lymphatic metastasis
The median RFS for the 14 patients with lymphatic
metastasis (including 3 patients with lymphangiosis
carcinomatosa) was 15.3 months (range, 4.2 to 59.8
months). The impacts of clinicopathological variables on
RFS for lymphatic metastasis are shown in Table 4. On
univariate analysis, depth of tumor invasion and number
of lymph node metastases were identified as risk factors
for lymphatic metastasis (P = 0.001, and P < 0.001,
respectively). On multivariate analysis, depth of tumor
invasion and number of lymph node metastases repre-
sented independent risk factors for lymphatic metastasis
(P = 0.023 and P = 0.007, respectively).
Discussion
This study examined differences in risk factors between
various patterns of recurrence in patients who under-
went surgical curative resections for advanced gastriccarcinoma. As a result, independent risk factors for each
recurrence pattern were identified as follows. For peri-
toneal metastasis, depth of tumor invasion, number of
lymph node metastases, and histological differentiation
were identified. For hematogenous metastasis, number
of lymph node metastases, and venous vessel invasion
were identified. For lymphatic metastasis, depth of
tumor invasion, and number of lymph node metastases
were identified.
Seeding of cancer cells into the abdominal cavity rep-
resents the first step in peritoneal metastasis. This
means that pT4 can reasonably be considered an inde-
pendent risk factor for peritoneal metastasis, as previ-
ously reported [3-6]. Histological differentiation was also
detected as a risk factor for peritoneal metastasis in
some reports [4,6-9]. Although some reports have de-
scribed lymph node metastasis as an independent risk
factor for peritoneal metastasis, as in our result
[4,5,10-12], the role of lymph node metastasis in peri-
toneal metastasis has been unclear. However, because
peritoneal recurrence occurred in patients with cancer
limited to the gastric mucosa or submucosa but with
Table 4 Univariate and multivariate analyses of recurrence-free survival for lymphatic metastasis
Variables n Cumulative recurrence
rate at 5-year (%)












G1 or G2 58 14.6
G3 or G4 74 27.9
Depth of tumor invasion 0.001 0.023
pT2 or pT3 64 7.7 1
pT4 68 31.2 4.70 (1.21 to 31.28)
Number of lymph node metastases < 0.001 0.007
pN0 or pN1 74 5.0 1
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by cancer cells has been suggested as the mechanism
underlying peritoneal recurrence [13,14]. Moreover, in-
jury to the lymphatic system during operative proce-
dures in patients with highly extensive metastatic lymph
nodes may allow the spread of viable cancer cells into
the peritoneal cavity [12].
The first step in hematogenous metastasis is invasion
of cancer cells into the lumen of the venous circulation.
Our finding of vessel invasion as an independent factor
for hematogenous metastasis is reasonable. The same re-
sult has been reported from other institutions [15,16].
However, vessel invasion is not incorporated as a factor
in the Union for International Cancer Control (UICC)
staging criteria or the Japanese classification of gastric
carcinoma. Attention should thus be given to hemato-
genous recurrence in patients showing vessel invasion,
even if the tumor stage is otherwise comparatively low.
Conversely, the number of lymph node metastases might
be an independent risk factor for hematogenous metas-
tasis because of the connection of lymphatic channels to
the systemic circulation via the thoracic duct. Noguchiet al. [16] reported venous invasion and lymph node me-
tastasis as risk factors for liver metastasis. Kodera et al.
[17] reported lymph node metastasis as a risk factor for
bone metastasis.
With regard to lymphatic metastasis, the number of
lymph node metastases and depth of tumor invasion
represented independent risk factors. In this study, how-
ever, lymphatic vessel invasion was not identified as a
risk factor for lymphatic metastasis, perhaps for the fol-
lowing reasons. First, cancer cells flow through lymph-
atic vessels to distant vessels. Cancer cells invading
lymphatic vessels are therefore sometimes not detected
in resected specimens. Second, lymphatic vessels are
sometimes difficult to distinguish from the venous vas-
culature. In addition, some lymphatic vessels are thought
to be destroyed by invasion of cancer cells, so patholo-
gists cannot always detect lymphatic vessel invasions
correctly. Third, if the number of cancer cells invading
lymphatic vessels is small, the invasion might not be
reflected in the patient prognosis. In addition, quantify-
ing the grade of lymphatic vessel invasion objectively
is difficult. However, the number of lymph node
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vessels. In our study, the number of lymph node metas-
tases was stratified into N0/N1 or N2/N3. This stratifica-
tion of lymph node metastasis may be considered to
reflect the amount of cancer cells invading lymphatic
networks better than the presence or absence of lymph-
atic vessel invasion.
As with our result, some reports have described the
number of lymph node metastases as a risk factor for
lymphatic metastasis [12,14]. The identification of pT4
as an independent factor for lymphatic metastasis might
reflect cancer cell invasion into the entire subserosal
layer through the abundant lymphatic vessels.
The status of lymph node metastasis has been identi-
fied as the most important prognostic factor in patients
undergoing gastrectomy [3,4,7,18-21]. This is reflected
in the fact that the number of lymph node metastases
represented an independent prognostic factor for all
three patterns of recurrence in the present study. As
mentioned previously, the number of lymph node me-
tastases might reflect the amount of cancer cells in
lymphatic channels in the peritoneum and both the
greater and lesser omentum. Preoperative neoadjuvant
chemotherapy for patients with a strong indication of
lymph node metastases might therefore be acceptable to
reduce seeding of cancer cells into the abdominal cavity
as the result of surgical procedures. However, no ran-
domized studies have yet addressed the survival benefits
of this approach [1]. Randomized controlled trials of
neoadjuvant therapy for patients with lymph node metas-
tasis are thus needed to clarify means of achieving better
prognosis in patients undergoing curative resection.Conclusions
Risk factors for recurrence after curative gastrectomy for
advanced gastric carcinoma differ between patterns of
recurrence. By paying more attention to the specific risk
factors of recurrence present in patients, the likelihood of
missing sites of recurrence could be decreased and recur-
rences identified earlier. This would allow appropriate
treatment to be initiated more quickly for patients with re-
currence. In addition, the status of lymph node metastasis
contributed to all patterns of recurrence, even peritoneal
metastasis. For patients in whom lymph node metastasis
is suspected preoperatively, neoadjuvant therapy might be
utilized to achieve better treatment outcomes.Abbreviations
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